Joseph Brewer

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

Joseph H. Brewer, MD, is an infectious disease doctor in Kansas City, and Assistant Clinical Professor of Medicine at the University of Missouri in Kansas City, United States. He is board certified in internal medicine.[1] Dr Brewer has been practising medicine for over 30 years, and has a private practice in Kansas City.[2] He has special interest in the effect of mycotoxins from mold on chronic illness and sees many patients with Lyme disease, ME/CFS, mold illness and environmental illness.[1][3]

Education[edit | edit source]

  • University of Kansas School of Medicine
  • University of Missouri School of Medicine - Kansas City (UKMC)
  • Emory University School of Medicine (Residency)[1]

Positions held[edit | edit source]

Brewer protocol[edit | edit source]

Dr. Brewer developed a treatment protocol after publishing his research findings on the effects of mold in chronic illness, which were co-authored with Jack Thrasher and Dennis Hooper. The protocol involves:

  • Use of intranasal sinus products to remove the biofilm from the nose and sinuses
  • Use of powerful antifungals, typically amphotericin and nystatin to destroy the mold or mycotoxins[4][5]

The Brewer Protocol aims to improve health by removing colonized mold or mycotoxins in order to stop frequent infections of the nasal passsages and sinuses.[4][6]

Notable studies[edit | edit source]

Clinic location[edit | edit source]

St. Luke's Hospital of Kansas City
Plaza Infectious Disease, PC
4320 Wornall Road, Suite 440
Kansas City, Missouri

Talks and interviews[edit | edit source]

Online presence[edit | edit source]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. 1.0 1.1 1.2 "Dr. Joseph H Brewer, MD - Kansas City, MO - Infectious Diseases". St Luke's Hospital, Kansas City. Retrieved October 25, 2021.
  2. 2.0 2.1 "Joseph Brewer, MD - Speaker Profile, ISEAI 2019 Conference". International Society for Environmentally Acquired Illness. 2019. Retrieved October 25, 2021.
  3. 3.0 3.1 "Medicine". Whittemore Peterson Institute. Retrieved October 25, 2021.
  4. 4.0 4.1 Woodlandhills Pharmacy. "Brewer Protocol". Woodland Hills Compounding Pharmacy. Retrieved October 25, 2021.
  5. "Brewer's Protocol". Forte Rx Compounding Pharmacy. Retrieved October 25, 2021.
  6. 6.0 6.1 Brewer, Joseph H; Hooper, Dennis; Muralidhar, Shalini (2015). Global Journal of Medical Research. Global Journals Incorporated. doi:10.17406/gjmrkvol15is5pg33.
  7. Brewer, Joseph H.; Berg, David (January 2001). "Hypercoaguable State Associated with Active Human Herpesvirus-6 (HHV-6) Viremia in Patients with Chronic Fatigue Syndrome". Journal of Chronic Fatigue Syndrome. 8 (3–4): 111–116. doi:10.1300/J092v08n03_10. ISSN 1057-3321.
  8. Brewer, Joseph; Thrasher, Jack; Straus, David; Madison, Roberta; Hooper, Dennis (April 11, 2013). "Detection of Mycotoxins in Patients with Chronic Fatigue Syndrome". Toxins. 5 (4): 605–617. doi:10.3390/toxins5040605. ISSN 2072-6651. PMC 3705282. PMID 23580077.
  9. Brewer, Joseph; Thrasher, Jack; Hooper, Dennis (December 24, 2013). "Chronic Illness Associated with Mold and Mycotoxins: Is Naso-Sinus Fungal Biofilm the Culprit?". Toxins. 6 (1): 66–80. doi:10.3390/toxins6010066. ISSN 2072-6651. PMC 3920250. PMID 24368325.